<DOC>
	<DOCNO>NCT02739685</DOCNO>
	<brief_summary>The purpose current study demonstrate non-inferiority everolimus-eluting bioresorbable vascular scaffold everolimus-eluting stent patient chronic total occlusion regard antirestenotic efficacy 8 10-month angiographic follow-up .</brief_summary>
	<brief_title>Bioresorbable Vascular Scaffolds Versus Stents Patients With Chronic Total Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Clinical inclusion criterion : Age ≥18 year Angina pectoris , equivalent symptom , and/or positive stress test Viable myocardium subtend chronic total occlusion Negative pregnancy test woman childbearing potential Angiographic inclusion criterion : Chronic total occlusion define Thrombolysis Myocardial Infarction flow 0 estimate duration ≥3 month Successful wire passage assumption successful stent/scaffold deployment Target reference vessel diameter 2.5 4.0 mm Clinical exclusion criterion : Limited longterm prognosis lifeexpectancy &lt; 12 month Contraindications antiplatelet therapy Known allergy cobalt chrome , everolimus , polylactic acid Angiographic exclusion criterion : Target lesion locate leave main trunk Target lesion locate coronary bypass graft Bifurcation lesion plan twostent strategy Indication coronary artery bypass grafting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>